ABCL Stock Clocks Best Week Since February On Clinical Data Anticipation, Baker Bros Stake Boost

• ABCL635 is being developed as a non-hormonal treatment for menopause-related vasomotor symptoms such as hot flashes.
• ABCL is pivoting to become a fully integrated clinical-stage biotech that develops and owns its own high-value medicines.
• According to data from Koyfin, 8 of the nine analysts covering ABCL stock rate it ‘Buy’ or higher, while one rates it ‘Hold.’

Shares of AbCellera Biologics Inc. (ABCL) continued their strong upward momentum on Friday, as investors gear up for the company’s first-quarter 2026 earnings report and a key clinical catalyst scheduled for Monday.

ABCL shares closed up 9% on Friday and edged up 4% after hours. Overall, the stock clocked 18% gains this week, clocking its best week since the last week of February.  

Upcoming Catalysts

On Monday, AbCellera will release its financial results alongside interim early-stage data for its lead internal candidate ABCL635 being developed as a non-hormonal treatment for menopause-related vasomotor symptoms such as hot flashes — an area with significant unmet medical need and an estimated multi-billion-dollar U.S. market opportunity.

AbCellera spent years building an antibody discovery engine and generating revenue primarily through partnerships. It is now deliberately pivoting to become a fully integrated clinical-stage biotech that develops and owns its own high-value medicines. ABCL635 is the first real test of that shift.

The positive sentiment was further reinforced this week by a regulatory filing showing that Baker Bros. Advisors, one of biotech’s most respected institutional investors, has increased its stake in AbCellera to 10.8% of outstanding shares.

Wall Street, on average, now expects the firm to report first-quarter revenue of $5.84 million, above the $4.24 million reported in the corresponding quarter of 2025, in addition to a loss per share of $0.19.

Analyst Takeaways

Earlier this week, Cantor Fitzgerald initiated coverage of AbCellera with an ‘Overweight’ rating and $7 price target. According to data from Koyfin, 8 of the nine analysts covering ABCL stock rate it ‘Buy’ or higher, while one rates it ‘Hold.’ The 12-month average price target on the stock is $9.14, representing a potential upside of about 74% from the last close.

How Did ABCL Retail Traders React?

On Stocktwits, retail sentiment around ABCL stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.

A Stocktwits user opined that the biggest question running up to Monday is how strong the data will be.

Another user voiced optimism for the catalysts driving the stock higher.

ABCL stock has gained 161% over the past 12 months. 

Read More: REPL, QURE, MRNA Soar On Reports Trump Will Fire FDA’s Marty Makary

For updates and corrections, email newsroom[at]stocktwits[dot]com.